Taysha Gene Therapies Announces Participation in Upcoming Investor Healthcare Conferences
February 10 2021 - 7:00AM
Business Wire
Truist Virtual Fireside Chat on February 11,
2021 at 1:00 pm ET
10th Annual SVB Leerink Global Healthcare
Conference on Friday, February 26, 2021 at 8:40 am ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
clinical-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
a virtual fireside chat for the Truist Fireside Chat series as well
as the 10th Annual SVB Leerink Global Healthcare Conference.
Conferences Details:
Event:
Truist Virtual Fireside Chat with
Joon Lee, MD, PhD, Director and Senior Biotech Equity Research
Analyst
Date:
Thursday, February 11, 2021
Time:
1:00 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder
and CEO
Dr. Suyash Prasad, Chief Medical
Officer and Head of R&D
Kamran Alam, Chief Financial
Officer
Dr. Kimberly Lee, SVP, Corporate
Communications and Investor Relations
Event:
10th Annual SVB Leerink Global
Healthcare Conference (Virtual)
Date:
Friday, February 26, 2021
Time:
8:40 am ET
Format:
Presentation
Participants:
RA Session II, President, Founder
and CEO
Audio webcasts for these conferences will be available in the
“Events & Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210210005323/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com Media Contact: Carolyn Hawley Canale
Communications carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024